The iconic rise of Viagra has consistently remained a benchmark of pharmaceutical success, however its future within the broader industry now triggers questions about potential returns . Alternative versions are eroding market share, prompting anxieties that investing in companies heavily reliant to Viagra's once-dominant position could be a danger